80%Confidence
0Views
FDASource
2026-03-19Date
Summary
Defective blister packaging for Midodrine tablets creates patient safety concerns for this blood pressure medication, potentially leading to product degradation and reduced efficacy. The packaging failure at Major Pharmaceuticals suggests quality control issues in their packaging operations that may affect other products.
Actionable: Verify packaging integrity for all products from Major Pharmaceuticals and consider temporary sourcing alternatives for Midodrine.
AI Confidence: 80%
Data Points
firmThe Harvard Drug Group LLC
classificationClass II
statusOngoing
distributionNationwide US.
productMidodrine Hydrochloride Tablets, USP, 5 mg, 50 Tablets (5 x 10 blister packs), Rx only, Packaged and Distributed by: Major Pharmaceuticals, Indianapol
Get Signals Instantly
Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.
Subscribe Now